| |
Glasgow: 48-Week Efficacy and Safety and Early CNS Tolerability of Doravirine, a Novel NNRTI, with TDF/FTC in ART-Naïve HIV-Infected Patients
|
| |
| |
Oral Presentation
Reported by Jules Levin
HIV Drug Therapy
Glasgow 2014
Josep M. Gatell1, Javier O. Morales-Ramirez2, Debbie P. Hagins3,
Melanie Thompson4, Keikawus ArastŽh5, Christian Hoffmann6, Sorin Rugina7, Olayemi Osiyemi8, Simona Erscoiu9, Robin Dretler10, Charlotte Harvey11, Xia Xu11, Hedy Teppler11 for the P007 Study Team
1Hospital Clinic/IDIBAPS. Univ of Barcelona, Spain; 2Clinical Research Puerto Rico, San Juan, PR; 3Chatham County Health Dept, Savannah, GA, USA; 4AIDS Research Consortium of Atlanta, Atlanta, GA, USA; 5EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 6ICH Study Center, Hamburg, Germany; 7Spitalul Clinic de Boli Infectioase, Constanta, Romania; 8Triple O Research Institute PA, West Palm Beach, FL, USA; 9Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes," Bucharest, Romania; 10Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 11Merck & Co., Inc., Whitehouse Station, NJ, USA
|
|
| |
| |
|
|
|
